Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

Clinical trial NCT07439887 · RECRUITING

Trial details

NCT number: NCT07439887
Sponsor: Ray Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Stargardt Disease

Start date: 2026-01-28
Primary completion: 2030-12-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.